The control group that received DNCB exhibited significantly elevated mRNA levels of inflammatory proteins associated with AD, such as TNF-α, interferon gamma (IFN-γ), interleukin IL-6, and IL-13. The gene discussed is IL13; the disease is Alzheimer disease.